Tucker Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Tucker Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-150	Closed	-$207	–	878
2022 Q3	$207	Hold	150	–	–	﹤0.01%	795
2022 Q2	$237	Buy	+150	New	+$198	﹤0.01%	615

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Tucker Asset Management's LCTX Position: Q4 2022 in Review

Tucker Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2022, closing a stake of 150 shares — an estimated $207 sold.

Tucker Asset Management first reported a position in LCTX in Q2 2022 and held it in 2 quarters. The position peaked at $237 in Q2 2022. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

Tucker Asset Management reported no remaining Lineage Cell Therapeutics position as of Q4 2022 after selling out during the quarter.
Tucker Asset Management sold 150 Lineage Cell Therapeutics shares in Q4 2022, an estimated $207.
Tucker Asset Management first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 2 quarters.
Tucker Asset Management's Lineage Cell Therapeutics position peaked at $237 in Q2 2022.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on Tucker Asset Management's 13F filing for Q4 2022, filed 11 May 2023.